Evidence map›Paper›PMID 39046263›Full record

Trial reportJournal of virology2024

Prediction of differential Gag versus Env responses to a mosaic HIV-1 vaccine regimen by HLA class I alleles.

George W Nelson, Janine van Duijn, Yuko Yuki, Maria G Pau, Frank Tomaka, Ludo Lavreys, Steven C DeRosa, M Juliana McElrath, Gregory D Kirk, Nelson L Michael and 7 more

Abstract readClinical Trial, Phase IIClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of virology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

George W NelsonBasic Science Program Frederick National Laboratory for Cancer Research, National Cancer Institute and Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.ORCID 0000-0003-1075-8459
Janine van DuijnJanssen Vaccines & Prevention, Leiden, the Netherlands.ORCID 0000-0002-5097-0713
Yuko YukiBasic Science Program Frederick National Laboratory for Cancer Research, National Cancer Institute and Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
Maria G PauJanssen Vaccines & Prevention, Leiden, the Netherlands.
Frank TomakaJanssen Research and Development, Titusville, New Jersey, USA.
Ludo LavreysJanssen Infectious Diseases BV, Beerse, Belgium.
Steven C DeRosaDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
M Juliana McElrathDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
Gregory D KirkDepartment of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.
Nelson L MichaelUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
David W HaasDepartment of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Steven G DeeksDepartment of Medicine, University of California, San Francisco, California, USA.
Steven WolinskyDivision of Infectious Diseases, Department of Medicine, The Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Bruce WalkerRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts, USA.
Dan H BarouchRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts, USA.ORCID 0000-0001-5127-4659
Daniel StiehJanssen Vaccines & Prevention, Leiden, the Netherlands.
Mary CarringtonRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts, USA.ORCID 0000-0002-2692-2180

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
LC: HIV Vaccine Trials NetworkUM1AI068618 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Margaret Juliana McElrath · 2011 to 2026
$483.6M
Northwestern CORE Clinical Research Site: Trans-omics for HIV/AIDS ResearchU01HL146240 · NHLBI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Frank J Palella, Valentina Stosor · 2019 to 2026
$31.5M
NCI NIH HHS 75N91019D00024NHLBI NIH HHS U01 HL146240NIAID NIH HHS UM1 AI068618
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AIDS VaccinesAllelesenv Gene Products, Human Immunodeficiency Virusgag Gene Products, Human Immunodeficiency VirusHIV-1HIV InfectionsAdultCD8-Positive T-LymphocytesFemaleHistocompatibility Antigens Class IHumansMaleViral LoadAIDS Vaccinesenv Gene Products, Human Immunodeficiency Virusgag Gene Products, Human Immunodeficiency VirusHistocompatibility Antigens Class IHIV proteinsHIV vaccineHLA class I

Identifiers

PMID39046263
PMCPMC11338073

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.